Anticoagulation and antiplatelet management in gastrointestinal endoscopy: A review of current evidence

Table 43 Polypectomy

Ref.	Year	Country	Study design	n	Polyp morphology	Procedure	Medication	Relative risk
Horiuchi et al[133]	2014	Japan	Prospective	35	Size: ≤ 10 mm	Polypectomy	Warfarin (continued)	Incidence of PPB 14%
Beppu et al[134]	2014	Japan	Retrospective	20	Size: ≥ 20 mm and < 20 mm	Polypectomy	Warfarin ± HBT (ceased at least 5 d before)	Incidence of PPB 52.2%
Yanagisawa et al[1]	2018	Japan	Retrospective	486	Size: < 10 mm or ≥ 10 mm	Polypectomy	Warfarin ± HBT (ceased 3-5 d before)	Incidence of PPB 13.7%. Incidence of PPB on HBT 21.7%
Lin et al[107]	2018	United States	Retrospective	427	Size: < 20 or ≥ 20 mm	Polypectomy	Warfarin ± HBT (ceased 3-5 d before)	Incidence of PPB 0.66%
Yu et al[127]	2019	United States	Retrospective	3471	N/S	Polypectomy	Warfarin ± HBT (ceased before procedure)	Incidence of PPB 1.2%
Kishida et al[41]	2019	Japan	Retrospective	6382	Size: < 10 mm or ≥ 10 mm	Polypectomy	Warfarin ± HBT (ceased 3-4 d before)	Incidence of PPB 2.3%. Incidence of PPB with HBT 20% (study did not discern rates between warfarin vs DOAC)
Amato et al[108]	2019	Italy	Prospective	n=1504	Size: ≥ 10 mm	Polypectomy	Warfarin(ceased median 5 d before)	Incidence of PPB 8.5% (anticoagulant monotherapy)(study did not discern rates between warfarin vs DOAC)

PPB: Post-procedural bleeding; HBT: Heparin bridging therapy; DOAC: Direct oral anticoagulant; N/S: Not stated.